Rwandan Health Minister Dr Sabin Nsanzimana

The first two people with Marburg also had malaria, which slowed down their diagnosis, Rwandan Health Minister Dr Sabin Nsanzimana told a media briefing on Thursday hosted by the Africa Centres for Disease Control and Prevention (Africa CDC).

This follows the revelation that the suspected index case died on 8 September, according to Dr Brian Chirombo, the World Health Organization’s (WHO) Rwanda representative, speaking at a global WHO briefing held at the same time. 

However, Nsanzimana stressed that Marburg was only confirmed on 26 September.

“The hospital that was attending to the first suspected cases raised the alarm, saying we’re seeing patients, two cases, that are not responding to usual [malaria] treatment. The symptoms for Marburg are very similar to those of  malaria,” said Nsanzimana.

“Its high fever, a severe headache, muscle pain and joint pain and fatigue, and later on, gastrointestinal [pain], nausea, vomiting.  For malaria-endemic countries, these are well known symptoms for malaria.”

As the first case was becoming very sick, Rwanda’s Biomedical Centre, the National Public Health Institute and National Reference Laboratory were called in to investigate and take samples. After running a multitude of tests, they eventually diagnosed Marburg last Thursday.

The outbreak, now comprising 36 confirmed cases, stems from a single cluster in Kigali. This is centred on the two hospitals that treated the earliest suspected cases – the University Teaching Hospital of Kigali (known as CHUK) and the King Faisal Hospital. 

All cases reported in other districts first had contact either with the index case or the health workers who treated him in the capital city before travelling elsewhere. However, the minister added that an Africa CDC map (below) of affected districts was slightly misleading as included districts with case contacts as well as cases.

Marburg outbreak, mapping both cases and location of contacts.

Nsanzimana confirmed that one case has been confirmed in the district alongside the Democratic Republic of Congo (DRC), but as the incubation period for Marburg is up to 21 days, more cases could emerge in the coming days.

Some 80% of Marburg cases are health workers, while new cases steam from their “very close contacts”, said Nsanzimana. Eleven people have died so far.

‘No travel ban’

Meanwhile, in the absence of a Marburg diagnosis, widow of the earliest known case travelled to Belgium. However, she did not have symptoms, had since tested negative and completed 21 days’ quarantine under the guidance of Belgian authorities.

A young German medical student who had been an intern in own of the hospitals had also returned to Germany, but had also tested negative for the virus.

However, the health minister said said his country would be tightening controls at airports. None of the contacts of cases would be allowed to leave the country until they had completed the 21-day quarantine. Thermal cameras were already in use at the siport to screen for people with high temperatures.

Earlier, the Rwandan government suspended visits to hospital patients and boarding school students.

However, Africa CDC Director General Dr Jean Kaseya was emphatic that “there is no travel ban policy”. He reported being inundated by people asking whether they should continue to travel to Rwanda.

“We are flying to Rwanda. I will be in Rwanda, attending meetings. It’s an outbreak that is managed and, as we have outbreaks in all other countries, there is no travel ban. And I repeat it: travellers should not cancel their trips to Rwanda,” said Kaseya.

Pipeline for Marburg vaccines and therapeutics

Dr Ana Maria Restrepo, WHO Co-Lead of R&D Blueprint for epidemics, said that while there were candidate vaccines and therapeutics for Marburg, “they don’t yet have the clinical efficacy data that will allow our colleagues in the regulatory team to proceed with emergency use listing”.

“WHO has been working with a consortium of over 180 researchers and developers from all around the world, and we hope that we all continue to work collectively and together to support the government Rwanda, to seek the opportunity to evaluate these candidates and therapeutics using a state of the art randomized trials,” Restrepo told the WHO press briefing.

In the absence of any approved treatment, Gilead has donated around 5000 doses of its anti-viral medication, remdesivir, which is being given to patients, said Kaseya.

Mpox continues to surge

Mpox cases, 2 October 2024

While mpox has been upstaged by the more deadly Marburg, there continues to be a steady uptick in cases – around 2,500 every week – said Kaseya.

Currently, there are 34,297 suspected cases but the confirmed cases remain a very low due 6,806 due to a myriad of logistical problems. Ghana this week became the 16th African country to confirm an mpox case.

Kaseya also reported that cases in DRC capital of Kinshasa had surged in late September, coinciding with the reopening of schools. Some 46% of all mpox cases are in children.

Trials would soon begin to test the efficacy of a new therapeutic drug, Brincidofovir, while another trial testing the efficacy of “fractional doses” of the current Bavarian Nordic MVA-BN vaccine is also imminent. If successful, this could massively reduce the need for vaccines, which are in short supply.

Meanwhile, the WHO’s director of regulation and pre-qualification, Dr Rogerio Gaspar, reported that the global body was on the brink of authorising Bavarian Nordic’s MVA-BN vaccine for children aged 12 to 17, and was still engaged with the Japanese producer of the vaccine LC16, which has emergency use listing.

Lenacapavir, packaged as Sunlenca in the US, where is sells for $42,250 for two injections.

HIV activists have hailed the announcement by Gilead on Wednesday that it has authorised six generic manufacturers to sell its breakthrough HIV treatment, lenacapavir, in 120 low- and middle-income countries. 

However, they have urged Gilead to expand the deal to include countries such as Brazil, Colombia and Mexico.

Lenacapavir is a long-acting injectable drug that has proven 100% successful in preventing HIV in women who received it twice a year, and almost 100% protective for men and gender minorities who have sex with men in clinical trials.

Results of the PURPOSE1 trial involving women were presented at the International AIDS conference in Munich in July, receiving a standing ovation.

In late September, results from the PURPOSE2 trial reported 99% success rate for the drug as pre-exposure prophylaxis (PrEP).

While lenacapavir is not yet authorised in many countries, it is licensed in the US as Sunlenca for people with drug-resistant HIV, and costs $42,250 a year for two injections.

A wide range of organisations, including UNAIDS, called on Gilead to lower costs and license generic companies to produce the injection. The company undertook to do so at a media briefing at the AIDS conference in July, 

On Wednesday, Gilead CEO Daniel O’Day announced it had signed voluntary licencing deals with the six generic companies to produce lenacapavir. Four of the companies are from India: Reddy’s Laboratories, Hetero Pharma, Emcure and Mylan (a subsidiary of Viatris). Egypt’s Eva Pharma and Pakistan’s Ferozsons Laboratories are also part of the deal.

“Given the transformative potential of lenacapavir for prevention, our focus is on making it available as quickly and broadly as possible where the need is greatest,” said O’Day.

“Gilead teams have been working with urgency to bring on high-volume generic manufacturers now, so that we can ensure a rapid transition to these voluntary licence partners after lenacapavir for PrEP is approved.”

Most of South America excluded

Activists at the International AIDS conference protesting against the high price of lenacapavir.

Public Citizen’s access to medicines director Peter Maybarduk said Gilead had “heard the call in part” from people living with HIV and allies worldwide to make lenacapavir “available for global, timely affordable supply, by licensing developing country manufacturers”.

“Its licence will help ensure access to needed treatment for many people and countries. But it leaves out others, including most of South America, where communities continue to fight against real challenges for access,” Maybarduk added.

“Gilead will continue to control who sells lenacapavir and where, through restrictive licensing terms, which will limit availability of affordable lenacapavir even where Gilead claims no patents.”

Public Citizen would have preferred Gilead to license the Medicines Patent Pool, which “would have helped Gilead reach as many people as possible through equitable access terms and brought added credibility”. 

UNAIDS applauded Gilead for licensing the generic companies – including one on the African continent – without waiting for registraion.

“Lenacapavir, which requires only two injections per year, could be game changing – if all who would benefit can access it,” noted UNAIDS.

However, it said that 41% of new HIV infections are in upper-middle income countries, so the “exclusion of many middle-income countries from the licenses is deeply worrying and undermines the potential of this scientific breakthrough”.

UNAIDS also welcomed Gilead’s statement of commitment to “non-profit pricing”, and urged the company to name a specific price.

“Respected researchers have shown it is possible to produce and sell lenacapavir for $100 per patient per year, falling to as little as $40,” it noted.

HIV advocacy organisation AVAC welcomed the speedy issuing of the licenses and the fact that the generic companies come from three different countries, but noted that “key countries with significant HIV incidence, including several of those hosting the PURPOSE 2 trials of lenacapavir” had been left out.

“This challenges the field’s ability to use this new option at the scale needed to drive down HIV incidence as quickly as possible to meet global targets,” said AVAC, noting that the price of lenacapavir is “still unknown”.

Untaid ‘prepared to invest immediately’ in generics

Meanwhile, Unitaid welcomed the announcement, adding that it is “prepared to invest immediately and collaborate to fast-track access to lenacapavir”.

Unitaid, an initiative hosted by the World Health Organization (WHO) that promotes equitable access to treatment for key global diseases, said it was ready to assist the six generic companies that have been licensed.

“This is a potentially game-changing medication that could dramatically turn the tide against HIV infections, and we must ensure, without delay, global access to lenacapavir for all those who need it,” said Dr Philippe Duneton, Unitaid’s executive director. 

Duneton urged Gilead to “expand its licensing framework to include all populations in need, clarify its plans for registration in all trial countries, and provide a clear timeline for when lenacapavir will be accessible in the countries it promises to serve”.

Brazil was one of the countries that hosted the PURPOSE trials and “cannot be excluded from licensing agreements, and registration plans,” noted Unitaid.

Unitaid, working with the Wits RHI (South Africa) and Clinton Health Access Initiative (CHAI), will soon launch an Expression of Interest for generic lenacapavir licensees to for support for “the accelerated development, regulatory filing, commercialisation, and cost-effective launch pricing for generic lenacapavir”. 

It also urged Gilead to ensure an access strategy that is “transparent, global, and equitable, prioritising those in greatest need wherever they live”. 

“There is an urgent need to understand what pricing policies would be put forward by Gilead, and whether the same populations excluded today from the possibility of acquiring lower-cost generic products in the future, will also be left with unaffordable for-profit prices.”

Story updated to include UNAIDS comment.

Image Credits: Gilead.

Health workers being briefed about Marburg in Rwanda.

Twenty-nine people in Rwanda have been diagnosed with Marburg, the deadly haemorrhagic virus, and 10 have already died, according to the country’s health ministry on Tuesday.

This is three more cases and four more deaths since the outbreak was announced last Friday.

The Rwandan Ministry of Education suspended visits to students in boarding schools on Wednesday to prevent the spread of the virus in schools. 

This follows Sunday’s decision by the health ministry to suspend hospital visits and restrict the funerals of people suspected to have died of Marburg, confining their size to 50 people and outlawing home vigils and open caskets.

Some 70% of those infected are health workers at two facilities in the Rwandan capital, Kigali, and the 19 surviving patients are currently in isolation in hospital, according to the health ministry.

Cases have also been detected in three districts bordering Rwanda’s neighbours, the Democratic Republic of Congo (DRC), Uganda and Tanzania.These countries have weaker health systems and surveillance than Rwanda, and there are fears of that the disease might already be in those countries.

Marburg in Rwanda, October 2024

However, an alarmist report suggesting that Marburg may have spread to Belgium is untrue.

“Contact tracing is underway, with about 300 contacts under follow-up as of 29 September 2024,” according to the World Health Organization (WHO).

“One contact travelled to Belgium from Rwanda. WHO was made aware of this by the public health authorities in Belgium. They shared detailed information on the contact’s situation, that they remained healthy, completed the 21-day monitoring period, did not present with any symptoms, and are not a risk to public health.”

Marburg update, 1 October 2024

Transmission via fruit?

There is no vaccine or proven treatment for Marburg, a zoonotic disease from the same filovirus family as Ebola. Between 20-90% of people with the disease will die, according to the US CDC.

However, there are “several promising candidate medical countermeasures that are progressing through clinical development”, according to the WHO Africa region, which is “coordinating a consortium of experts to promote preclinical and clinical development of vaccines and therapeutics against Marburg virus disease”.

The Sabin Vaccine Institute’s vaccine candidate began Phase II trials in humans a year ago,.

The first known cases were identified in 1967 in Marburg, Germany, in people suspected of coming into contact with infected monkeys from Uganda.

Since then, Egyptian fruit bats have been identified as reservoirs for the Marburg virus.  Human contact between infected bats, including exposure to their urine and faeces, as well as contact with primates infected by bats are the main suspected routes of transmission.

However it is also possible that people could be infected via fruit, according to a 2021 study by Brian Amman of the Viral Special Pathogens Branch at the US CDC and colleagues.

They showed that Marburg-infected bats “can shed virus onto discarded fruit” that can remain stable for around six hours on mangoes and bananas, fruits that are enjoyed by bats and primates, including humans. 

“Consuming or handling of fruit bitten or spat-out by bats is a risk factor” for Marburg spillover to humans and other sensitive wildlife, according to the study.

But person-to-person transmission “requires extremely close contact with a patient,” according to the Africa Centres for Disease Control and Prevention (Africa CDC).

“Infection results from contact with blood or other body fluids (faeces, vomit, urine, saliva, and respiratory secretions) with high virus concentration, especially when these fluids contain blood. Transmission via infected semen can occur up to seven weeks after clinical recovery.”

The incubation period varies from two to 21 days. Thereafter, illness “begins abruptly, with high fever, severe headache and severe malaise”. 

On the third days, patients may experience “severe watery diarrhoea, abdominal pain and cramping, nausea and vomiting”.

“Although not all cases present with haemorrhagic signs, severe haemorrhagic manifestations may appear between five and seven days from symptoms onset, and fatal cases usually have some form of bleeding, often from multiple areas,” Africa CDC notes.

Keep calm, urges health ministry

Rwandan Health Minister Dr Sabin Nsanzimana appealing for calm on national television on Sunday.

Rwanda’s Ministry of Health has urged Rwandans to “remain vigilant and strengthen preventive measures by ensuring hygiene, washing hands with soap, sanitizing hands, and taking necessary precautionary measures when in contact with other individuals”.

Health Minister Sabin Nsanzimana has also appealed for calm, saying that people can continue with their daily lives as the government “has begun to identify hot spots”. However, he appealed to those with symptoms to seek immediate health from their nearest health facility or via an emergency number.


The same infection prevention and control protocols used for other viral haemorrhagic fevers, such as Ebola, should be followed to prevent transmission, according to the WHO Africa Region.

In a joint effort with USAID, WHO has delivered over 500 clinical care, infection prevention and control supplies to Rwanda.

Image Credits: Ministry of Health, Rwanda.

Dr Joachim Hombach (left), WHO senior health advisor to SAGE and Dr Kate O’Brien, WHO Director of Immunization lay out new recommendations on RSV, rubella and polio vaccination.

For the first time ever, the World Health Organization (WHO) has recommended that pregnant women be vaccinated against respiratory syncytial virus (RSV), or that their newborns receive a dose of monoclonal antibodies to protect them against severe RSV disease, which has seen a global resurgence as the COVID-19 pandemic waned. 

In 2022-2023, RSV was the second most detected virus (10.9%) after SARS-CoV-2 (22%), after two seasons of low circulation, presumably due to pandemic-era restrictions. 

The new guidance on RSV, another new recommendation aimed at accelerating the pace of rubella vaccination in under-5s, as guidance on polio jabs and others, were all issued by WHO’s Strategic Advisory Group on Immunization (SAGE) at a press conference on Wednesday. 

The guidance came against data showing that routine vaccinations in 2023 still had not caught up with pre-pandemic levels. 

“In 2023, there were 14.5 million children who didn’t get even a single dose of vaccine.” noted  Dr Kate O’Brien, Director of WHO’s Department of Immunization, Vaccines and Biologicals, at the briefing.  

“Before we hit the pandemic, that number was 12.8 million children, so the world has not recovered back to the performance that was already achieved before we hit the pandemic.

World lags in vaccinating ‘zero dose’ children 

Africa was one of only two WHO regions that in 2023 reduced the number of ‘zero-dose’ never reached by any vaccinations.

That leaves Gavi, The Vaccine Alliance, also behind on its target of reducing the number of ‘zero-dose’ children by 25% by 2025, the Alliance said yesterday in its annual progress report, also issued on Wednesday. 

However, there was good news for the Africa region, which was one of only two regions in the world that saw a decrease in the number of ‘zero dose’ children who have not been reached by any routine immunization programs. 

“The Africa region actually had a decrease in the number of zero dose children in 2023 compared with 2022 which is really good news,” O’Brien said. 

“And in addition to that, the Africa region was one of, again, a limited number of regions that also had a decrease in the number of children who did not receive a measles vaccine. That has fallen to 11.5 million children, compared with 12.2 million children in 2022,” O’Brien said. 

Progress globally in HPV vaccination 

Girls wait after receiving HPV vaccinations at a primary school in Masaka, Rwanda; in 2023, Africa’s HPV vaccine rates were among the highest in the world.

Both SAGE and Gavi report also noted progress on the drive to eliminate cervical cancer by immunizing 14 million girls with the HPV vaccine. There too, the African region stood out with the greatest gains in immunization rates of almost any other region in the world, O’Brien said.  

“With 14 million girls vaccinated against HPV with Gavi support… this number is greater than the previous 10 years combined.” said Gavi in a press statement. “Gavi has now helped prevent over 600,000 future deaths from cervical cancer alone and is on track to reach 86 million girls by the end of 2025.”

RSV recommendation includes two options  

RSV
In May, 2023, GSK’s Arexvy vaccine became the first to be approved for use against the respiratory syncytial virus (RSV), which WHO has now recommended for pregnant women.

The RSV recommendation to countries comes in two parts: either introduce the new RSV for pregnant women in their third trimester to protect their fetus against congenital RSV, preventing the disease in newborns. Alternatively, countries might opt to administer a single dose of monoclonal antibodies to the newborn babies themselves, the SAGE panel recommended.

There are pros and minuses of each approach. The RSV monoclonal antibody remains very expensive to procure. But clinical vaccine trials also have indicated a safety “signal” of slightly more pre-term births among women who get the vaccine – although the increase was very small and  outweighed by the survival gains of newborns whose mothers were vaccinated.

“Close to 97% of the [RSV] related mortality is estimated to occur in low and middle income countries,” said SAGE chair Dr Hanna Nohynek. “We now have, after 60 years of waiting, … two interventions to prevent RSV in children, that is maternal immunization and then monoclonal antibodies to small children.

“SAGE recommended that all countries should introduce passive immunization to prevent severe RSV disease in children, and that could take place either by maternal vaccination or by this monoclonal antibody.  

“In the vaccine efficacy studies, there was a documented safety observation of imbalanced preterm delivery in two trial sites with maternal vaccination, mainly in South Africa and Argentina, and SAGE looked into this signal. But considering the risks and the benefits, and clearly there is a major benefit to be expected,” she said, adding that researchers would continue to collect more data on the pre-term birth issue. 

Rubella vaccine recommended universally

Infant in Rwanda receives a combined measles and rubella vaccine. WHO has now recommended that rubella should be included in routine vaccination, even In countries falling short on measles vaccination.

In another piece of significant, but technically nuanced advice, SAGE also recommended that rubella vaccine be administered “universally” in countries, even if they haven’t yet reached an  80% rate of measles vaccination. 

About 32,000 infants a year are born with congenital rubella syndrome, an insidious form of the disease that causes severe heart defects and intellectual disability. Those cases mostly occur in just 19 countries with historically low overall vaccination rates. 

Previous WHO recommendations held that countries should achieve 80% coverage with at least an initial dose of measles vaccine – with measles being used as a proxy for a country’s immunization outreach capacity.  

That was due to concerns that in countries with low-vaccination rates overall, introduction of the rubella vaccine could actually increase environmental exposures of girls and pregnant women to the rubella virus overall, and thus cause even more CRS cases in newborns. 

But new modeling work and analysis shows that the 80% threshold rate is “overly conservative and no longer warranted,” the SAGE experts said in a press statement.  

Six of the 19 remaining countries with no rubella containing vaccine (RCV) are now planning to introduce it, and SAGE recommends that the vaccine thus be introduce in the 13 remaining countries.

“The universal introduction of RCV, accompanied by wide age-range campaigns at introduction, should be initiated in the remaining 13 countries. Regular follow-up campaigns are recommended in countries where routine MCV coverage is below 90%,” SAGE said.

Reinforcement of polio vaccines 

The September campaign to vaccinate children with oral polio dose in conflict-wracked Gaza reached its 90% coverage goal. WHO now recommends a jab of inactivated virus, as well, in situations where that’s feasible.

SAGE also recommended that during polio outbreaks, and subsequent vaccine campaigns, a jab of inactivated poliovirus (IPV) be administered along with the oral polio vaccine (OPV), so as to better reinforce the immunity of children at risk.

Adding the injection would help better protect against environmental exposures to vaccine-derived poliovirus, in outbreaks such as the one seen recently in Gaza, as well from exposures to wild poliovirus, still circulating in countries such as Afghanistan and Pakistan, WHO said, adding “unless it would impact the timeliness of the response.” 

Currently, WHO and country partners are in the process of phasing out the bivalent OPV and replacing it with a novel OPV vaccine that does not mutate as easily in the environment to cause new infections in other young children. 

However, two doses of OPV are needed to build the required immunity, with a weaker response in undernourished children, while recent studies have shown that the IPV has a reinforcing response in the gut to the OPV vaccine, whatever type was administered, as well as protecting from polio’s most severe outcome, paralysis, and that is a boost to at-risk children generally.  

“The whole intention here is to shift over to a world where we no longer give oral polio vaccine, but we are relying in that end stage of polio eradication on injectable form of of the vaccine,” pointed out O’Brien, noting that in most developed countries that shift has already happened, and IPV is the only vaccine that infants and young children already receive.

“So including the injectable polio vaccine along with the oral polio vaccines whenever there’s an outbreak,… and including the injectable form of the polio vaccine for the preventive campaigns, wherever that is possible, provides a sort of dual protection in order to enhance the immunity and to protect against the possibility of circulating [vaccine-derived] strains that could transform into ones that that cause paralysis.”

Weighing vaccine costs, benefits and scientific evidence 

Cutting across all of the WHO’s recommendations are issues of vaccine costs, as well as nuanced considerations of benefits that can be obtained – and the gaps in knowledge that countries must weigh up in decision-making. 

“Fifty years ago, there were seven diseases against which we have vaccines today. Today there are over 30 diseases that are vaccine preventable. And there has been a huge success rate in developing vaccines in the past 15 to 20 years,” O’Brien said, leading to “more vaccines available than any country can take up.”

More and more vaccines are constantly being developed, particularly with the recent introduction of new technologies, such as mRNA. That leaves countries forced to weigh up an increasing array of factors, including the scientific evidence and data around relative costs and benefits of various choices. 

“So we’re really in a new era of vaccine development and vaccine deployment,” she said. “But it really depends also on the characteristics of the disease and the characteristics of the vaccine relative to that disease, in order to achieve that ultimate end point of disease prevention, which is the most equitable kind of disease prevention we could ever have, which is complete eradication of the disease

But the increase in vaccine options also means that more and more countries are struggling with questions around the evidence of a vaccine’s benefits against costs, and many of the newest vaccines and solutions may also remain out of reach until prices come down.

Price drops usually only happen when a vaccine becomes available in generic form or agencies such as Gavi procure the jabs in bulk on behalf of low- and middle-income countries.  

“Vaccine is not a prevention tool unless it’s actually used,” O’Brien remarked.  “And so this is at the heart of vaccination programs: that they get to the countries that need them.”

Image Credits: Flickr – UNICEF Ethiopia, University of Oxford/Tom Wilkinson, UNICEF, NIAID, WHO, WHO.

Thousands protest anti-LGBTQ laws in Budapest, Hungary in 2021.

UNAIDS expressed “deep concern” Wednesday over Georgia’s newly adopted anti-LGBTQ+ law, saying that it could threaten progress made over the past decade to end AIDS in the former Soviet republic of 3.7 million people at the crossroads between Europe and Asia. 

The new legislation exacerbates stigma and hinders “LGBTQ+ people’s access to essential health services” which “undermines Georgia’s efforts to end AIDS and combat other infectious diseases,” said the UN agency in a press statement

UNAIDS has long called out the risk such legislation poses to public health efforts to control HIV and other infectious diseases – leaving at-risk groups even more reluctant to seek out health services for fear of stigmatization and even prosecution.

The UNAIDS comments echoed a statement issued by the UN Office for the High Commissioner of Human Rights’ saying the new law will “impose discriminatory restrictions on education, public discussion, and gatherings related to sexual orientation and gender identity.”

Georgia’s new law on “family values and protection of minors”  bans Pride events and public displays, as well as censoring related films and books. 

It follows moves by several other European countries – including Hungary and Poland – to curb LGBTQ+ rights. Nearly a dozen African countries have criminalized LGBTQ+ relationships, with some instituting stiff penalties, including the death penalty or life in prison. 

Georgia’s move comes after a recent study from the European Union’s Fundamental Rights Agency, which found that 14% of people who identified as a sexual minority experienced some form of violence. 

While UNAIDS and other international organizations have decried such laws, they remain popular in socially conservative countries. A 2018 poll from the Washington DC-based National Democratic Institute suggested that only 23% of Georgians believe that protecting the rights of sexual minorities is important. Similarly, a 2022 poll suggested that only 0.99% of Georgians agree that homosexuality is “justifiable” compared to 62% of Canadians and 45% of Americans. 

Anti-LGBTQ+ legislation could “undermine” fight against infectious diseases

Georgia historically has reported low rates of HIV infections, with new infections concentrated in persons who inject drugs (PWIDs) and men who have sex with men (MSM). 

Yet its Georgia country report states that the prevalence of HIV – the number of people living with the disease – remains “alarmingly stable” at 21.5% for the MSM population, suggesting that the most at-risk groups still are not being reached. Worryingly, 36% of people living with HIV were not aware of their positive HIV status. 

Furthermore, the UNAIDS country report found that over 40% of Georgians believe that HIV positive children should attend schools with HIV negative children, noting:  “Stigma kills, but solidarity saves lives. Upholding the rights of LGBTQ+ people is crucial to advancing public health, social cohesion, and equality for all.”

Image Credits: Lydia Gall/ Human Rights Watch.

WHO Director General Dr Tedros Adhanom Ghebreyesus greets Afrigen’s Prof Petro Terblanche at the mRNA facility in South Africa

The establishment of an “mRNA hub” in South Africa to build the capacity of low- and middle-income countries (LMICs) to develop vaccines during the COVID-19 pandemic was widely hailed as a solution to Africa’s lack of manufacturing ability.

But three years after its launch in June 2021, the hub faces uncertainties, risks and shortfalls –  including that it may simply become a “technological solution” that maintains the status quo rather than a genuine transfer of knowledge and capacity to LMICs, according to a recent report

Authors Professor Matthew Herder, chair in Applied Public Health at Dalhousie University in Canada and Ximena Benavides from Yale University in the US, base their observations on interviews with 35 key players and numerous documents, some of which were obtained via an access to information request to the Canadian government.

The hub is the initiative of the World Health Organization (WHO) and the Medicines Patent Pool (MPP). Spurred by the failure of high-income countries to share their COVID-19 vaccines at a time of extreme need, the WHO and MPP selected a South African consortium comprising biopharmaceutical company Afrigen Biologics, vaccine producer Biovac and the SA Medicines and Research Council, as its partner to kickstart a facility capable of developing and producing mRNA vaccines in a LMIC. 

Once this was done, they were to teach other facilities in LMICs across the world how to do the same.

The mRNA programme currently includes the South African consortium and 14 other LMIC-based partners.

The current mRNA programme partners

Championing voluntary IP transfer

But the way in which the hub is governed and operates does not sufficiently transfer power and capacity to LMICs, the authors contend.

“The architects of the programme are working within the existing system of biopharmaceutical production and, at the same time, preserving their own control over the programme’s design and preferred measures meant to remedy shortfalls in equitable access to mRNA-based interventions,” they argue.

“In particular, MPP continues to champion voluntary [intellectual property] licensing as the optimal means to improve local production capacity in LMICs even though that mechanism did not attract collaboration from more established mRNA manufacturers in the context of COVID-19 and slowed adoption of a more transformative end-to-end approach to R&D and manufacturing.”

They also argue that the “technological outcomes” of the programme are uncertain unless there is “significant reform and concerted effort to redistribute not just IP, but agency to LMIC actors”.

Without these “there is a significant risk that the programme, which is claimed by WHO and MPP as a collective effort to improve manufacturing capacity in LMICs for LMICs, will not solve the problem of equitable access to biopharmaceutical innovation”.

‘In line with status quo’

While the mRNA programme may improve the sharing of knowledge, the authors observe, it has been developed “in line with the status quo” of global biopharmaceutical production.

This includes “weak conditionalities around product affordability, participants’ freedom to contract with third parties, and acceptance of market-based competition”, they argue.

The WHO and MPP also exert “tight control over the programme” and this “evokes the dynamics that are often in play in global health, to the detriment of empowering LMIC-based manufacturers to generate mRNA products in response to local health needs”, they argue.

For example, the MPP has created its own technology transfer unit to manage technology transfer within the mRNA programme. But typically, technology is transferred from one party with direct experience in using it, to another, through sharing hands-on know-how. 

“I’ve worked for more than 30 years in the industry. You do not have a remote group that does tech transfer. If a group is going to do tech transfer, it needs to be in the facility that’s sending the technology out,” one participant told the authors.

The hub’s donors – France, the European Commission, Germany, Norway, Belgium, Canada, South Africa and the African Union – have committed $117 million to the programme (with $89 million received so far).

But some of the high-income countries (HICs) that have invested in the mRNA programme have also made demands that have shaped the programme. Canada, for example, stipulated that its funding be allocated to the hub in Cape Town and four other countries only: Senegal, Nigeria, Kenya and Bangladesh.

“According to one interview participant, while HICs are supportive of transferring technology to LMICs, they would prefer that such transfers do not extend to the more upstream inputs into mRNA vaccine production, including novel LNPs and antigens,” the authors note.

Charles Gore (MPP), Petro Terreblanche (Afrigen), WHO’s Dr Tedros Ghebreysus,South Africa’s Health Minister Dr Joe Paahla, and Anne Tvinnereim, Norwegian Minister of International Development, at the ribbon-cutting to formally open Afrigen  on 20 April, 2023.

Contradictory legal agreements – and pricing silence

The report notes that the MPP has crafted a set of legal agreements including a technology transfer template in which LMICs are granted a “non-exclusive, royalty-free, non-sublicensable, non-transferable, irrevocable, fully paid-up, royalty-free licence” to the technology.

They also get access to any rights held by Afrigen and Biovac “to make, or have made, use, offer for sale, sell, have sold, export or import” products in their respective territories and other LMICs.

In exchange, LMICs must grant MPP a worldwide, non-exclusive, royalty-free licence to data and the inventions to “facilitate the development and equitable access of health technologies”.

Brazil’s Bio-Manguinhos has baulked at the idea that technology it has developed with  funding from the Brazilian government “would flow to manufacturers from participating LMICs, which in some cases, are for-profit commercial entities, without anything in return”, with official Patricia Neves describing this as an “injustice”.

South Africa also contested the absence of royalties, and its agreement with MPP states that any licence may include a “royalty sacrifice”.

Meanwhile, Indonesia’s BioFarma negotiated the right to sell products to HIC. 

“MPP also stopped short of requiring that resulting mRNA products be priced affordably for populations in need outside of a Public Health Emergency of International Concern (PHEIC),” the authors note.

If an mRNA product developed by an LMIC partners targets a PHEIC, they cannot charge more than the cost of production plus a 20% mark-up.

“Traditionally, MPP has not interfered in pricing. Our model is based on competition, and clearly we are potentially giving this to 15 companies around the world,” MPP executive director Charles Gore told the authors.

In response, the authors remark that the MPP “appears to be comfortable relying on free-market competition among LMIC-based manufacturers instead of imposing affordability clauses when it comes to products generated by virtue of participating in the mRNA programme”.

Moving beyond COVID

A researcher in the WHO mRNA hub at Afrigen in South Africa.

It took Prof Petro Terblanche’s Afrigen only two months to develop an mRNA vaccine for COVID-19 based largely on a Moderna “recipe” published online. It has since transferred this knowledge to facilities in countries including Bangladesh, Serbia and Brazil.

But the urgency related to COVID-19 has passed. Expanding the programme’s focus upstream is now seen as crucial to its overall sustainability given that demand for COVID-19 vaccines is limited. 

At a meeting in Bangkok in late 2023, WHO and MPP officials outlined “potential sub-consortia – engaging partners both inside and outside of the programme – focused on R&D around pathogens of shared, regional interest,” according to the authors.

Afrigen is increasingly focusing on the development of second-generation technologies important in mRNA production, such as novel lipid nanoparticles (LNPs), and new disease targets like TB, malaria and HIV.

“The critical question is whether the funding that has been secured for the programme and supporting the development of these second-generation mRNA technologies has been leveraged into a shared set of commitments geared towards improving equitable access,” the authors note.

While Afrigen targeted 11 potential diseases for mRNA product development, its proposals focusing on Lassa fever, RSV, and other disease targets have been turned down by a variety of funders.

Terblanche has conceded that her “hand will now be forced to prioritise” in favour of market rewards – particularly as the MPP expects the programme to be “self-sustaining” by 2026.

But an increasing number of “use patents” that claim IP on the use of mRNA technology are being filed in South Africa and other LMICs, and these threaten to block Afrigen and partners’ R&D plans.

Recalling that some of the companies that took part in the the influenza vaccine hub later shut down production, WHO’s Martin Friede estimates that if a handful of LMIC manufacturers manage to make mRNA vaccines, the programme will be an overall success.

Meanwhile, MPP’s Gore noted that “we are funding [Afrigen] to develop and then shift [the technology] out,” but “they don’t [yet] have a business model.”

MPP’s Marie-Paule Kieny speculates that Afrigen will, in the end, probably yield to market forces: “The hub is really there to establish a first platform and improvement, and to help with an early pipeline. After that we are fully aware that Afrigen is a private company, at one point they will try to find somebody to buy them out and to get the benefit,” she told the authors.

‘Failure of imagination’

But the authors describe the “near inevitability of Afrigen’s exit in the eyes of those who designed the programme” as an indication of the “underlying failure of imagination concerning how the mRNA programme is governed”. 

A more “inclusive and decentralised” governance structures could “shield initiatives such as the mRNA programme from the risks and constraints posed by dominant market actors”. 

This decentralized structure could involve “representatives from participating LMICs capable of steering the programme’s R&D towards local population” in the overall governance and day-to-day decision-making., they argue.

“Second, multiple actors would need to serve as regional mRNA hubs – as originally planned – in order to mitigate the risk that one organization’s failure (or acquisition by an outside actor) might compromise the programme as a whole,” they argue.

“Instead, WHO and MPP internalised programme decision-making within two hand-picked committees [the “Scientific and Technical Review Committee and the mRNA Scientific Advisory Committee], leaned on private actors like Afrigen to play crucial roles, preserved their discretion about what projects and partnerships to pursue, and limited input from LMIC governments and civil society during the programme’s first two-plus years of operation,” they note.

“It remains to be seen whether MPP, which has ascended in the sphere of global health during the pandemic as a result of its role as the central power broker for the entire mRNA programme, will over time cede some of its control and take the steps necessary to truly empower LMIC manufacturers,” they observe.

Health Policy Watch will publish an interview with the Medicines Patent Pool responding to these findings shortly.

Image Credits: WHO, WHO, Kerry Cullinan.

Ukrainian children are suffering extreme stress from being under constant bombardment by Russian air strikes.

BAD HOFGASTEIN, Austria — Strokes in children are now common in Ukraine as Russian air strikes rain down death, stress and trauma on civilians for a 947th day, Ukrainian Health Minister Viktor Liashko said on Wednesday.

“We see strokes in children aged 12 to 13,” Liashko said. “Before the war, such cases were really unique. But now, our health system has children with strokes.”

Inna Ivanenko, Director of Patients of Ukraine, the nation’s largest patient organization, added in an interview she knows of even younger stroke victims.

“Ten,” she said quietly.

The surge in pediatric strokes is just one facet of the escalating health crisis affecting Ukrainian civilians, the country’s health minister said. Years of war have left the entire population, not just children, at higher risk due to extreme stress and untreated post-traumatic stress disorder (PTSD).

“People have strokes 10 to 15 years earlier,” Liashko said. “Also heart attacks, 10 to 15 years earlier.”

The physical toll of prolonged stress is well-documented, particularly in conflict zones. Research links untreated PTSD and extreme stress to higher rates of strokes, heart attacks and an array of other cardiovascular diseases. These range from ischemic heart disease to high blood pressure and atrial fibrillation — a heartbeat irregularity that can cause blood clots and raise stroke risk.

This gets worse during wartime. The first-ever systematic review of links between armed conflict and cardiovascular disease, published in the British Medical Journal, found that war is associated with higher rates of heart problems, including strokes.

Further evidence published by the National Institutes of Health in 2023 found PTSD was associated with a 59% higher risk of incident stroke. The British Heart Foundation also found associations of PTSD with increased risk of stroke and other cardiovascular diseases. 

In wartime Ukraine, researchers in the southwestern city of Ivano Frankivsk found a 22% increase in stroke episodes in the population from 2022 to 2023. The study attributes the spike to “increased psychosocial stress … among Ukrainians affected by the Russo-Ukrainian War.” 

While the paper was not focused on children, its authors warn an entire generation of young Ukrainians will be affected in the long run. 

“Based on the situation in the country, we predict that stroke incidences will, unfortunately, continue to grow,” the researchers wrote. “Especially considering that war-induced PTSD targeting the young population typically manifests later in life, commonly in the form of cardiovascular problems, such as stroke.” 

For the next generation, many still hold out hope for a brighter future.

“Sixty thousand children were born in bomb shelters during these two and a half years,” he said. “They were born because their mothers wanted to save their lives. They wanted them to start their life in this world with hope of a better life.”

Ukrainian Health Minister Viktor Liashko

Targeted Russian strikes on health escalate

As the war enters its third year, the indirect consequences of Russia’s military actions are mounting. Direct attacks on civilians mesh with frontline casualties, stretching Ukraine’s medical resources to the breaking point. The relentless demand for emergency care compounds an already critical situation.

“All of this causes an influx of patients and our facilities have to respond,” Liashko said. “Where should our priorities be? Pediatric, or should it be care facilities for elderly people? Infectious diseases or cardiac diseases? Or do we have to redirect our resources to hospitals and clinics that help to cope with mental disorders?” 

The health minister further described the difficulties in responding to wartime emergencies, noting health services often need to evacuate people for complex surgeries and treat polytraumas inflicted by explosives and gunfire. 

“Sometimes it is not possible to start treatment with just one team. We need surgeons, traumatologists,” Liashko said. “It takes a lot of time and is very expensive. All of this is conducted under the circumstances of air alarms and interruption of energy supplies.” 

The number of surgeons in Ukraine has increased by nearly 25% since 2023, from 55,000 to 68,000 currently active across the country, as medical professionals adapt to the growing need amid an explosion of wartime injuries. Despite the surge, many regions still face dire shortages. 

In the eastern region of Zahporzhia – just 20 kilometers from the frontline and 70% occupied by Russian troops – complex surgeries are at their most challenging. Russia has destroyed hundreds of medical buildings across the region including the main hospital that served tens of thousands of people.

“We have a lack of specialists, [particularly] different kinds of surgeons, anesthesiologists and other kinds of specialists,” Zahporzhia mayor Ivan Fedorov said via video link from his office 30km from the frontline. “Our citizens … need care. We have no other choice.” 

Two residents stand in the ruins of homes in Borodianka in the Kyiv region.

The unrelenting assault on Ukraine has also inflicted a heavy toll on the mental health on all of society. An estimated 90% of Ukrainians – civilians, generals, doctors, and politicians – require mental health support. 

The number of patients requiring psychological or psychiatric assistance nearly doubled in the first year of the war, with over 375,000 Ukrainians now receiving active care. The Ministry of Health estimates 3.5 million Ukrainians will develop a mental disorder due to the war – 800,000 of those being of moderate to severe. 

“Every day, from five to seven hours per day, we hear air alarms. Enemy shelling doesn’t stop for any silence a day,” Fedorov said. “The greatrest problem is mental health. All our citizens, also doctors, fear for their futures. Nobody knows if they sleep, they can wake up tomorrow.” 

With psychiatric facilities overwhelmed nationwide, Ukrainians are learning to address mental health problems on their own. Nearly 100,000 non-specialists have completed online training to manage mental health issues and help others cope with stress, fear and anxiety, according to government figures. 

“We don’t only have physical injuries – we have mental health,” Liashko said. “We can’t talk about this later. If we wait for later, we will have a big problem.” 

Ukrainian children are vulnerable to multiple stresses because of the ongoing Russian war.

Cost in lives and dollars 

Another consequence of attacks on the health sector is delayed diagnosis of rare diseases and chronic conditions easily detectable in peacetime. These delays come with a high price — in lives and dollars.

“As a rule, these are simple treatments, but only for the first stage,” said Ivanenko, the patient organization leader. “The huge issue for us is the expensive medications of the second, third, fourth stage of treatment for cancer, for rare diseases. They are not available in the country due to budget limitations.”

Ukraine’s health system covers 60% of medications and all treatment for rare and late-stage diseases but doesn’t routinely buy expensive drugs for advanced stages of illnesses like cancer or rare conditions. This gap often leads to reliance on foreign donors for individual patients’ specialized care.

“Through international partners and donors, we can access these therapies through donations. We can help such people in a manual way, but it’s not systematic” Ivanenko explained. That’s why it is very important to invest in the Ukrainian healthcare system to allow systematic treatment access for these patients.” 

Inside the destroyed medical clinic in Kachkarivka, which is littered with detritus left behind after Russian forces were forced to withdraw in November 2022.

Ukraine’s health system has endured 2,013 direct attacks on personnel, hospitals, ambulances and primary care facilities since the full-scale invasion began, causing $7 billion in damages, according to the WHO Surveillance System for Attacks on Health Care.

In March 2024, Russia’s tactics evolved. Targeting Ukraine’s power grid became a priority, threatening the health system’s stability as it faces a third wartime winter. Attacks on telecom infrastructure further cripple hospitals’ communication and civilians’ access to 103, the emergency number for medical help.

“We have a winter coming, and that puts additional pressure,” said Dr Jarno Habicht, director of the World Health Organization’s (WHO) Ukraine office. “That pressure comes not only because we have below-zero temperatures, but because the Russian Federation continuously attacks energy infrastructure.”

A July report by WHO and Ukraine’s Health Ministry found significant power outages in 13% of the country’s hospitals. The assessment, shared with Health Policy Watch, revealed that a third of facilities with generators couldn’t use them, and 16% of all generators were offline.

Even functioning generators serve only as temporary solutions.

“Reserve generators can run for four or eight hours,” said Fedorov. “We need to be ready to work without electricity for three, four days. Nobody knows yet. That’s why we need to be ready.”

Russia targets power grid

The United Nations Office for the Coordination of Humanitarian Affairs warned last week that ongoing attacks on Ukraine’s power grid could leave citizens without electricity for up to 18 hours a day this winter. The grid is already 50% destroyed, with only 40% of its prewar power generation capacity remaining.

“This will have huge implications for health care, but also everybody who is at home,” Habicht said. “Can you imagine that you are living 18 hours per day without electricity? Keep that in your mind when we go through the winter.”

For now, the onslaught has failed to cripple Ukraine’s health system, with WHO reporting that more than 90% of medical facilities are still functioning. Health workers — from doctors, to nurses, to front-line clinic operators — work 24- to 36-hour shifts to keep the lights on. Some spend time living in the hospital wards. 

Over 200 health workers have been killed.

“We have lost too many health care workers because of the attacks, too many ambulances,” said Habicht. “But human lives are more important. We can buy new ambulances. We are losing health care workers because the war goes on.”

As the death toll on Ukraine’s health workforce mounts, several hundred more remain in Russian captivity. Some have been there for over two years.

“Ukrainian health care staff who are kept as prisoners of war contrary to the Geneva Convention must be freed,” Liashko said. “Russia does not allow them to be assessed by anybody, to check under which circumstances they are kept, or if they receive medical services.”

“Please exert pressure so Ukrainian health workers are freed as soon as possible and come back to Ukraine.” 

Image Credits: UNICEF, Matteo Minasi/ UNOCHA, Lily Hyde/ The New Humanitarian.

WHO Director-General Dr Tedros Adhanom Ghebreyesus, (left) and Dr Vanessa Kerry, CEO of the health non-profit Seed Global Health (middle) in conversation with Ravi Agrawal, editor-in-chief of Foreign Policy (right).

Specific health actions need to be included in countries’ climate targets – officially called the Nationally Determined Contributions (NDCs) – according to several health advocates speaking at the UN Climate Week in New York City over the past week.

“Our agenda should be health-centric,” said Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO), speaking on the sidelines of the annual UN General Assembly.

“We need to use the resources wisely, meaning targeting those populations, affected populations and then from there of course you can move to the rest because resources are limited,” Tedros said.

The demand for a holistic view in framing NDCs to ensure a “healthy and stable future” in was also reiterated in a signed letter by 20 leading civil society organizations and sent to officials at the UN Framework Convention on Climate Change (UNFCC), the entity supporting global response to climate change.

The rise in extreme weather events, such as heatwaves and floods, are directly impacting health and healthcare facilities. 

Dr Vanessa Kerry, CEO of the health non-profit Seed Global Health, called for health to be “embedded in the NDCs”. 

“We need to have health metrics, and we need to stop thinking about it as a sunk cost, but rather as an investment,” Kerry said. 

Centering health at COP

This decade, health has already gone from being a side note at the annual UN Climate Conference of Parties (COP) to having a day dedicated to the subject at the last COP in Dubai, United Arab Emirates (UAE). 

Both the Baku (Azerbaijan) COP presidency, which will  host this year and the Belém (Brazil) COP presidency, which will host next year, said that they aim to integrate health into climate conversations further.  

“Brazil was hit this year with the biggest dengue epidemic for ever, and this was the very consequence of the climate change and the high temperature that we are facing in Brazil and in all of the world,” said Ethel Maciel, Brazil’s Secretary of Health Surveillance and Environment.

She added that health equity will be a major focus and that Brazil has appointed a specific coordinator to work on the link between climate change and health equity.

The speed and extent of action though rely also on resources. For instance, the UAE recognized that having the resources and universal health coverage helps as they have the building blocks for what you need to be healthy. 

“We would say, for the nationally determined contributions, please embed [and] institutionalize targets for health in there, be they things like the impact of air pollution on health, be they heat stroke, be they mental health issues, number of events prevented. Whatever they are, please institutionalize certain metrics of health inside your nationally determined contributions,” urged Prof Maha Taysir Barakat, Assistant Minister for Health and Life Sciences in the UAE Ministry of Foreign Affairs. 

Prof Maha Taysir Barakat, Assistant Minister for Health and Life Sciences in the UAE Ministry of Foreign Affairs

Dr Maria Neira, WHO’s director of Environment, Climate Change and Health, drew attention to the fact that access to renewable energy will improve health by reducing air pollution.  

“So now we need to use health as a motivation. The health argument that we are taking to the COPs has to be extremely strong, and we are the ones that needs to engage,” she said, referring to the health sector.  

Working with cities for impact

It has become clear over the years that national governments are slow to move on climate targets. In addition, when it comes to the climate and health link, a range of stakeholders are needed for effective response. 

The Baku COP Presidency has an initiative on climate resilient cities of which health will be a big part. 

Patty O’Hayer, global head of corporate affairs at Reckitt, said that city mayors need to be supported to bring out change as they have a unique perspective and don’t work in silos. 

“Cities give you that kind of umbrella way that you can look at all of those aspects and make sure that you’re spending your time, your effort, your energy around the social determinants of health, decarbonizing the health care systems and thinking about public health in a much more holistic way,” she said. 

 

 

Health workers examine an mpox patient

Governments and donors have pledged around $1 billion to combat Africa’s mpox outbreak in the past few weeks, with the US pledging $500 million this week, said Dr Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention.

But the continent’s response is confounded by poor surveillance, problems with testingm virtually non-existant contact tracing (less than 4%) and insufficient knowledge about transmission, Kaseya tols a media briefing on Thursday.

Africa CDC and the World Health Organization (WHO), who are coordinating the continental response, were due to meet US Health Secretary Xavier Beccera late Thursday to discuss how the US money would be allocated.

However, the White House stated earlier in the week that the money will address a range of needs identified by the Africa CDC and WHO, including “training frontline health workers, disease surveillance, laboratory diagnostic supplies and testing, clinical case management, risk communication and community engagement, infection prevention and control, and research”. 

The Pandemic Fund has made $129 million available for 10 countries, while African countries have availed around 10% of funds raised.

Vaccine donations hit 4.3 million

Some 4,3 million vaccine donations have also been pledged. The bulk – three million – are from Japan for the Democratic Republic of Congo (DRC), the epicentre of the outbreak. The US also promised one million vaccines this week.

The Coalition for Epidemic Preparedness Innovations (​​Cepi) has allocated around $72 million (in partnership with vaccine producer BioNTech) for mpox vaccine development, and $145 million to support the expansion of the manufacturing capacity in Africa, especially in Rwanda, said Kaseya. 

But only a small percentage of the vaccine donations have touched down on African soil. The DRC is due to roll out its vaccination efforts next week but it has to navigate poor roads, lack of trained staff and armed conflict.

Given the scarcity of vaccines, vaccines will be confined to priority groups starting with the contacts of confirmed cases and healthcare workers, explained Dr Ngashi Ngongo, Africa CDC’s Chief of Staff, at a media briefing on Thursday.

Dr Ngashi Ngongo, Africa CDC Chief of staff

Others priority groups are “key populations, meaning commercial sex workers and men and having sex with men”, children, people in refugee camps, prisoners, truck drivers, cross-border traders and those who are immunocompromised, particularly those living with HIV.

Fifteen African countries have reported mpox cases since the beginning of the year while a further 15 are vulnerable, Kaseya told the media briefing.

In the past week, 2,910 new cases have been reported but only 436 have been confirmed, said Kaseya. Since the beginning of the year, over 32,000 suspected cases have been reported yet less than one-fifth have been confirmed.

Major weaknesses in surveillance, laboratories and research are confounding efforts to stem the spread of mpox. 

“Our immediate priorities are enhanced surveillance, contact tracing and laboratory testing,” said Kaseya.

Only about half the suspected mpox cases are being tested, and around 40% positivity rate  – but the results were tainted by the quality of the specimens, poorly trained staff as well as tests picking up other diseases such as measles and chicken pox, explained Ngongo.

About a third of cases have no apparent links to other cases, but Ngongo said this was likely because contact tracing is weak – with health workers only reaching around 3% of those who had been in contact with cases.

“Community-based surveillance is weak because the community health workers and community health programs have not been involved fully involved into the mpox response,” Ngongo noted. 

The mpox incidence management team, headed by Africa CDC and WHO, is encouraging countries to increase the number of community health workers, and the DRC plans to roll out the 40,000 community networkers, he added.

West’s failure to act on mpox Clade I

Africa CDC Director-General Dr Jean Kaseya.

Kaseya said that “our colleagues from Western countries” are also responsible for the huge rise in mpox cases in Africa.

“When we had the mpox public health emergence of international concern in 2022, they focused just on Clade II because that was in Europe and the US. They knew that there was a Clade I in Africa but didn’t conduct research on Clade I.”

Clade I has mutated into Clade Ib, which appears more infectious and more deadly. But because of international neglect, there is no rapid test for Clade I.

“We do not have a full understanding of the epidemiology of mpox and the transmission dynamics,” said Kaseya. “What are some of the factors that, for example, explain the high numbers of children that are being infected?

“About 80% of unknowns are mostly because our colleagues and partners didn’t want to see the reality,” he added.

Africa CDC has also sounded the alarm about possible cross-border transmission via truck drivers, who were key in transmitting HIV across the continent.

“Uganda’s 212 cases are just the tip of the iceberg. Knowing the cross border movement, mostly with truck drivers, and the weakness of our surveillance system, no one can say that these 212 suspected cases are accurate,” said Kaseya.

 He also questioned whether Tanzania, which has not officially reported any cases, really is mpox-free given its proximity to affected neighbours.

Image Credits: Africa CDC.

UN High Level Meeting, presided over by heads of FAO and UNEP (far left), and WHO WOAH (right), approves new declaration to fight AMR.

A UN High Level Meeting on Antimicrobial Resistance (AMR) pledged to reduce by 10% deaths from drug resistant bacteria over the next six years in a new declaration on the “silent, slow-motion pandemic” that could kill some 39 million more people by 2050.

Thursday’s milestone statement, the first on the topic since 2016, also pledges to raise $100 million to fund the updating of countries’ AMR action plans and their implementation. 

It also formalizes the standing of the Quadripartite secretariat made up of the World Health Organization (WHO), UN Environment (UNEP), the Food and Agriculture Organization (FAO), and the World Organization of Animal Health (WOAH), as the body coordinating global AMR response across the human, animal and environmental sectors.  

 Step forward despite no target for reducing animal antibiotic use

Mia Mottley, Prime Minister Barbados, at press briefing on on AMR threat before the HLM session.

The final draft of the declaration failed to include an earlier target to reduce the animal use of antibiotics by 30% by 2030, due to pressure from meat-producing nations and the farm industry. 

This, critics say, remains a serious shortcoming in the final draft as livestock use comprises as much as 73% of global sales of a range of antimicrobial agents (including antibiotics, antivirals and antiparasitics). 

Even so, the initiative was hailed as a major step forward in spurring more action on trends that few governments have fully recognized until very recently. 

“This declaration.. is an impressive blueprint for action,” declared Barbados Prime Minister Mia Mottley, who has become a global leader and advocate on AMR. 

“But the truth is the hard work starts tomorrow,” she said. “We’ve set a very, very modest target of $100 million [for national plans of action] and I hope that we can reach out to the leaders within the private sector, the pharmaceutical industries, the meat industries, all of the various players. 

“Because, as I’ve said very often with climate, unless they have a plan to live on a different planet, then we have to define the win-win solution for us all.”

No country is immune

WHO Director General Dr Tedros Adhanom Ghebreyesus at the UN High Level Meeting on AMR.

 “No country is immune to this threat, but low and middle income countries bear the greatest burden,” WHO Director General Dr Tedros Adhanom Ghebreyesus warned in his remarks.

“The threat of AMR cuts across the health of humans, animals, agriculture and our environment, and so must its solutions,” Tedros added.  “That’s why WHO, FAO and UNEP are working together closely with the World Organization for Animal Health (WOAH) in a One Health approach.” 

While 90% of countries have developed AMR action plans, only 11% of countries have allocated budgets to implement those plans, he said. 

As next steps, Tedros said that WHO and other members of the Quadrapartite would set up an independent science panel to produce a major report synthesizing evidence for more action on AMR by 2025.  WHO would also update its decade old global strategy on AMR by 2026. 

Deaths from superbugs 

New drug resistant bacterial strains are emerging more and more rapidly after the introduction of new antibiotics: WHO

Drug resistant bacteria are estimated to have killed an estimated 1.14 million people in 2021, and were somehow associated with the deaths of 4.71 million people, according to estimates published in The Lancet in mid-September. 

In the declaration, countries committed to reducing annual AMR deaths by 10% using a 2019 baseline level of mortality. In that year, 1.27 million deaths were attributed to drug resistant bacteria while 4.95 million deaths were somehow associated with drug resistant infections.  

Should global efforts to curb AMR fail, drug resistant pathogens could become the number one cause of death by 2050, warned Mottley at a press briefing just ahead of the High Level Meeting.

That would mean just going to the dentist, or getting cut doing garden work could lead to life threatening infections for some people “purely because of the ineffectiveness of the antibiotics,” Mottley warned.

“This, therefore, is a press conference not for us with grey hairs, so much, but for the young people in the world because they are the ones who will have to face the possible threat of a reversal of a century of medical progress in what we dub the ‘silent, slow motion pandemic,'” Mottley said.

Even so, AMR has already hit millions of families in the world, including her own, with tragic results, she added: “When I started this journey, I didn’t know it would become personal for me and my family, and I pray that no family has to experience what we did with respect to the loss of someone purely because of the ineffectiveness of antibiotics to be able to deal with infection.”

Four pronged assault – priorities for health and environmental sector 

The declaration outlines a four-part strategy to combat AMR. It calls for more careful use of antimicrobial agents in healthcare, farming, and animal sectors, alongside improved management of untreated sewage and hospital emissions. These emissions create environments where microbes from urine and feces can mutate and develop resistance to antibiotics, which are also released by hospitals and communities.

There is an urgent need for new antibiotics in many classes – and too few products in R&D.

Tedros, Mottley and others also called out the alarming dearth of new antimicrobials in the product pipeline. 

The number of pharma firms working on new antibiotics has declined substantially since 2000 due to the perception that there is little profitability in producing new products that can’t be used in large volumes, precisely because that may foster a spiral of new resistance risks.  

Mottley said that antibiotics should be recognized as a “global public good” with “dedicated financing”’ that goes beyond commercial investments.  

“I hope, therefore, that the World Bank in the general discussion as to its own reform and its movement towards the finance of global public goods and the guardian of global public commons, will be able to see appreciable progress in its reform efforts, so that this can be one of the early beneficiaries…  because…, this is as much an existential crisis.” 

Tackling fake medicines, sewage discharge and hospital emissions

Inger Andersen, United Nations Environment Programme at the UN High Level Meeting.

Tackling fake and substandard medicines, which can also lead to emergent resistance, is another huge priority cited in the declaration. And along with reducing overuse of antibiotics at risk of becoming impotent, as per WHO’s AWaRe classifications, there is a need to improve access to the right antibiotic formulations in low- and middle-income countries, where many more people still die from lack of any access whatsoever, Tedros emphasized. 

Moreover, some 56% of sewage effluent discharged is untreated, leaving cesspools of pathogens to breed and develop in lakes, rivers and aquifers of developing countries, in particular, pointed out Inger Andersen, Executive Director of the UN Environment Programme. 

Prevention is key to stop antimicrobials from leaking into our environment from municipal wastewater, from municipal waste, as well as wastewater from pharmaceutical production, hospitals, and farms that over use and intensify crop production sprayed with antimicrobials, Andersen added.  

“The pharmaceutical sector can strengthen inspection systems, change incentives and importantly, we can change subsidies and ensure adequate waste and waste management containment,” Andersen said. 

“The food and agriculture sector can take preventive action to limit the use of antimicrobials and to reduce the discharge from crops and terrestrial and aquatic, marine and animal and fish production facilities and the healthcare sector can improve access to high quality, hospital-specific wastewater treatment systems.

“This will take political determination, she stressed. “This will take leadership. These actions and more must be backed at the highest level, with policies, with laws and with regulations to reduce effluent releases.”

Animal use remains ‘elephant’ in AMR arena

Most of the world’s antibiotics sold are consumed by livestock not people – where they are often use as growth promoters or to prevent, rather than treat, infections.

But in terms of sheer volumes of use, antimicrobial use in the livestock sector remains one of the biggest threats to curbing AMR trends. It is estimated that some 73% of antimicrobials sold globally are used in livestock production, including continued use of antibiotics as growth agents in many nations.

Dropping the 30% target for their reduction significantly weakens the armory of the new declaration, observers said. 

“The AMR political declaration heralds a major shift in the global health response for AMR notably with the inclusion of commitment for targets and accountability including the recognition of the Quadripartite Joint Secretariat as the central coordinating mechanism as well as the call to establish an Independent Panel” said Dr Haileyesus Getahun, CEO of the South-South HeDPAC partnership. He led the foundation of the Quadripartite Secretariat, and served as its first director, in a previous role at WHO. 

“But it is very disappointing to see that the Muscat Manifesto targets on the 30% reduction of antimicrobial use in animals is not included, despite endorsement by 47 countries, ” he added, referring to a November 2022 declaration issued at the end of a High-Level Ministerial Conference on AMR hosted by the Sultanate of Oman in Muscat as part of the lead-up to the 2024 UN High Level Meeting. 

“Commitment for the targets would have galvanised county-level action not only to strengthen the animal health system but also the research and development for alternatives to antimicrobials,” Getahun said.

It is unfortunate that there was a major push back by the animal food industry who were able to influence some member states and even divide the Quadripartite organizations on this very topic.”

WOAH cites its plans for action in animal sector

Emmanuelle Soubeyran, WOAH Director General, speaking at the UN HLM.

There is, however, increasing recognition that overuse of antibiotics and other antimicrobials also represents an economic threat to the meat and dairy industry as the drugs will also become less effective in animal populations, asserted new WOAH Director General, Emmanuelle Soubeyran, at the HLM meeting.

“Drug resistant pathogens could jeopardize food security for over two billion people globally, more specifically on livestock, if no action is taken,” she said. 

“The impacts of AMR on livestock could reduce global GDP by $40 billion per year,” she said.  “But achieving a global 30% reduction in animal antimicrobial use within five years can raise [global] GDP in 2050 by €14 billion. 

“Thus, the World Organization for Animal Health welcomes the political declaration in alliance with our four priorities.”

Improving access to animal vaccination as an alternative to antimicrobials

Soubeyran said that improving access to animal vaccinations for vaccine-preventable diseases can reduce unnecessary use of antimicrobials. 

“We welcome your commitment to define animal vaccination strategies with clear implementation plans… and we’ll update the priority list of diseases of which vaccines could reduce antimicrobial use.”

At the same time, she admitted that the animal sector needs to do more to reduce its use of drugs deemed by the WHO to be “highest priority” for use in human health – and not animals. 

“The use in animals of highest priority antimicrobials to human health has been globally reduced to 16%,” she said.  “Regulation, awareness campaign, trainings, and public private partnerships have allowed such developments. 

“But we strongly encourage all of you, all of our members, to accelerate along this line. So, the important gaps still observed in the compliance with our international standards are closed.”

Economic carrot and stick

Since 2015, WOAH has seen the number of countries reporting quantitative data on antimicrobial use in animals increase three-fold, with 130 member states [of 183] now reporting, she added at a press briefing just before the HLM.

At the same time, the Paris-based WOAH, unlike FAO, WHO and UNEP, is not a UN-affiliated agency. Member states’ reports of their antimicrobial use are voluntary and not made public, leaving researchers to cull regional and country data from surveillance data on international drug sales in the animal health market. 

For instance, a  2019 WOAH report on trends in use of antibiotics as growth promoters, showed a decline in the practice. But not all 183 member states report data, and WOAH does not name the 45 countries that did report but continue antibiotic use for growth promotion.  

Among countries that continue to use antibiotics as growth promoters, the overall use of antibiotics is much higher overall, without much regard for risks, Soubeyran acknowledged. 

“Some 76% of WOAH members still using antimicrobials as growth promoters have not carried out a risk assessment … and countries using antimicrobials for growth promotion in livestock have an estimated average of 45% higher antimicrobial use than countries that do not use growth promoters.” 

Despite the resistance to change, emerging new economic data showing how antimicrobial abuse in livestock could lead to big economic losses over time, while judicious use will yield economic benefits, could begin to make a difference to the industry and policy makers. 

 “It is something very important to say to the sector,” she said. 

Image Credits: Yvan Hutin/WHO, IFPMA, Flickr: Paul van de Velde.